Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-Current Deferred Tax Liability: 2015-2021

Historic Non-Current Deferred Tax Liability for ImmunityBio (IBRX) over the last 5 years, with Dec 2021 value amounting to $162,000.

  • ImmunityBio's Non-Current Deferred Tax Liability fell 4.71% to $162,000 in Q2 2022 from the same period last year, while for Jun 2022 it was $162,000, marking a year-over-year decrease of 4.71%. This contributed to the annual value of $162,000 for FY2021, which is 96.65% down from last year.
  • According to the latest figures from FY2021, ImmunityBio's Non-Current Deferred Tax Liability is $162,000, which was down 96.65% from $4.8 million recorded in FY2020.
  • ImmunityBio's 5-year Non-Current Deferred Tax Liability high stood at $4.8 million for FY2020, and its period low was $162,000 during FY2021.
  • Over the past 2 years, ImmunityBio's median Non-Current Deferred Tax Liability value was $2.5 million (recorded in 2020), while the average stood at $2.5 million.
  • Data for ImmunityBio's Non-Current Deferred Tax Liability shows a maximum YoY tumbled of 96.65% (in 2021) over the last 5 years.
  • ImmunityBio's Non-Current Deferred Tax Liability (Yearly) stood at $498,000 in 2017, then reached $4.8 million in 2020, then tumbled by 96.65% to $162,000 in 2021.